Evidence map›Paper›PMID 34910784›Full record

ArticlePLoS pathogens2021

The RGD-binding integrins αvβ6 and αvβ8 are receptors for mouse adenovirus-1 and -3 infection.

Manuela Bieri, Rodinde Hendrickx, Michael Bauer, Bin Yu, Tania Jetzer, Birgit Dreier, Peer R E Mittl, Jens Sobek, Andreas Plückthun, Urs F Greber and 1 more

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Construction and application of adenoviral vectors.Molecular therapy. Nucleic acids · 2023
    Review
  9. Article
  10. Targeting integrin pathways: mechanisms and advances in therapy.Signal transduction and targeted therapy · 2023
    Review
  11. Review
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Manuela BieriDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.
Rodinde HendrickxDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0001-7161-4526
Michael BauerDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-8156-4603
Bin YuNational Engineering Laboratory for AIDS Vaccine, School of Life Sciences, Jilin University, Changchun, China.
Tania JetzerDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-9678-3622
Birgit DreierDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.
Peer R E MittlDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.
Jens SobekFunctional Genomics Center Zurich, Eidgenössische Technische Hochschule (ETH) Zurich and University of Zurich, Zurich, Switzerland.
Andreas PlückthunDepartment of Biochemistry, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-4191-5306
Urs F GreberDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-2278-120X
Silvio HemmiDepartment of Molecular Life Sciences, University of Zurich, Zurich, Switzerland.ORCID 0000-0002-4238-2217
University of Zurich · CHJilin University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mammalian adenoviruses (AdVs) comprise more than ~350 types including over 100 human (HAdVs) and just three mouse AdVs (MAdVs). While most HAdVs initiate infection by high affinity/avidity binding of their fiber knob (FK) protein to either coxsackievirus AdV receptor (CAR), CD46 or desmoglein (DSG)-2, MAdV-1 (M1) infection requires arginine-glycine-aspartate (RGD) binding integrins. To identify the receptors mediating MAdV infection we generated five novel reporter viruses for MAdV-1/-2/-3 (M1, M2, M3) transducing permissive murine (m) CMT-93 cells, but not B16 mouse melanoma cells expressing mCAR, human (h) CD46 or hDSG-2. Recombinant M1 or M3 FKs cross-blocked M1 and M3 but not M2 infections. Profiling of murine and human cells expressing RGD-binding integrins suggested that αvβ6 and αvβ8 heterodimers are associated with M1 and M3 infections. Ectopic expression of mβ6 in B16 cells strongly enhanced M1 and M3 binding, infection, and progeny production comparable with mαvβ6-positive CMT-93 cells, whereas mβ8 expressing cells were more permissive to M1 than M3. Anti-integrin antibodies potently blocked M1 and M3 binding and infection of CMT-93 cells and hαvβ8-positive M000216 cells. Soluble integrin αvβ6, and synthetic peptides containing the RGDLXXL sequence derived from FK-M1, FK-M3 and foot and mouth disease virus coat protein strongly interfered with M1/M3 infections, in agreement with high affinity interactions of FK-M1/FK-M3 with αvβ6/αvβ8, determined by surface plasmon resonance measurements. Molecular docking simulations of ternary complexes revealed a bent conformation of RGDLXXL-containing FK-M3 peptides on the subunit interface of αvβ6/β8, where the distal leucine residue dips into a hydrophobic pocket of β6/8, the arginine residue ionically engages αv aspartate215, and the aspartate residue coordinates a divalent cation in αvβ6/β8. Together, the RGDLXXL-bearing FKs are part of an essential mechanism for M1/M3 infection engaging murine and human αvβ6/8 integrins. These integrins are highly conserved in other mammals, and may favour cross-species virus transmission.

Indexed as

AdenoviridaeAdenoviridae InfectionsAnimalsAntigens, NeoplasmHumansIntegrinsMiceReceptors, VirusAntigens, Neoplasmintegrin alphavbeta6integrin alphavbeta8IntegrinsReceptors, Virus

Identifiers

PMID34910784
PMCPMC8673666
OpenAlexW4200201172

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.